Postsynaptic scaffold proteins such as Shank, PSD-95, Homer and SAPAP/GKAP family members establish the postsynaptic density of glutamatergic synapses through a dense network of molecular interactions. Mutations in SHANK genes are associated with neurodevelopmental disorders including autism and intellectual disability. However, no SHANK missense mutations have been described which interfere with the key functions of Shank proteins believed to be central for synapse formation, such as GKAP binding via the PDZ domain, or Zn2+-dependent multimerization of the SAM domain. We identify two individuals with a neurodevelopmental disorder carrying de novo missense mutations in SHANK2. The p.G643R variant distorts the binding pocket for GKAP in the Shank2 PDZ domain and prevents interaction with Thr(−2) in the canonical PDZ ligand motif of GKAP. The p.L1800W variant severely delays the kinetics of Zn2+-dependent polymerization of the Shank2-SAM domain. Structural analysis shows that Trp1800 dislodges one histidine crucial for Zn2+ binding. The resulting conformational changes block the stacking of helical polymers of SAM domains into sheets through side-by-side contacts, which is a hallmark of Shank proteins, thereby disrupting the highly cooperative assembly process induced by Zn2+. Both variants reduce the postsynaptic targeting of Shank2 in primary cultured neurons and alter glutamatergic synaptic transmission. Super-resolution microscopy shows that both mutants interfere with the formation of postsynaptic nanoclusters. Our data indicate that both the PDZ- and the SAM-mediated interactions of Shank2 contribute to the compaction of postsynaptic protein complexes into nanoclusters, and that deficiencies in this process interfere with normal brain development in humans.
Shank/ProSAP proteins, encoded by SHANK1-3 genes, are master scaffold proteins of the postsynaptic density (PSD) that link glutamate receptors to the actin cytoskeleton by integrating intermediate scaffolding proteins in dendritic spines. They share a set of domains including a Shank/ProSAP N-terminal (SPN) domain, a set of multiple ankyrin repeats (Ank), a Src homology 3 (SH3) domain, a PSD-95/discs large/ZO1 (PDZ) domain, a long Proline-rich region and a C-terminal sterile alpha motif (SAM) domain [1, 2]. The Shank PDZ domain constitutes the binding site for the PDZ ligand of SAPAP/GKAP proteins (termed GKAP from here on) that mediates an indirect interaction between Shank proteins and the NMDA receptors through binding to postsynaptic scaffold proteins of the PSD-95 family [3, 4]. Actin binding proteins cortactin, IRSp53 and Abi-1 [5,6,7,8,9,10] as well as Homer, an interaction partner of the metabotropic glutamate receptors (mGluRs) and IP3 receptors [11, 12], bind to the proline-rich region of Shank proteins. In the presence of Zn2+, the SAM-domain polymerizes into helical fibers, which may be stacked side-by-side through interhelical contacts. This enables the formation of large sheets where Shank proteins multimerize, allowing Shank proteins to serve as building blocks in deeper layers of the PSD [1, 13].
Shank proteins are concentrated in so-called nanoclusters, together with several direct and indirect interaction partners (Homer, GKAP proteins, PSD-95). It is assumed that nanoclusters serve to perfectly align the presynaptic release machinery with postsynaptic receptor-associated complexes [14, 15]. So far, it is unclear which principles govern their assembly.
Loss-of-function mutations [16,17,18,19,20,21,22] as well as rare missense variants [23,24,25,26,27,28] in all three SHANK genes are associated with neurodevelopmental disorders. Interestingly, the most widely studied functional domains of Shank proteins, such as the PDZ and SAM domains, and the cortactin and Homer binding sites are not functionally affected by missense mutations. Only in SHANK2, missense mutations have been reported which alter residues close to, or in the PDZ domain: S610Y; N690S in schizophrenia cases , and V717F in autism . However, a functional effect on the PDZ-mediated interaction has not been analyzed. Consequently, the role of these core interaction motifs of Shank proteins in the pathogenesis of neurodevelopmental disorders is unclear.
Here, we report two patients with de novo missense mutations in SHANK2, p.G643R and p.L1800W, which affect two key functional domains of the Shank2 protein, the PDZ and the SAM domain, respectively. Both variants disrupt the molecular interactions of the respective domains. We provide structural explanations for these deficits through homology modeling and crystal structure analysis. Both variants interfere with the targeting of Shank to dendritic spines and alter synaptic transmission. Moreover, the L1800W mutation decreased the number of dendritic clusters positive for Shank2. STED microscopy revealed that both mutants affect the nanoscale organization of PSD by decreasing the number of Shank2 nanoclusters at synapses.
Materials and methods
Patients and genetic analysis
We report two patients affected by a neurodevelopmental disorder. Informed consent for genetic analysis was obtained from parents, and genetic analysis was performed as approved by the Institutional Review Board (approval number by the Ethics Committee of the Hamburg Chamber of Physicians: PV 3802). Genetic testing was performed by trio IDEA (Intellectual Disability, Epilepsy, and Autism) panel analysis, or trio whole-exome sequencing of the patients and parents. In both cases a heterozygous, de novo missense mutation was identified in patients. Clinical and molecular findings for patient 1 are summarized in the Supplementary Data, and in Table S1. The contact to the family of patient 2 was lost during follow-up; therefore, no protected health information (PHI) for this patient is included in this paper.
Modeling of the extended PDZ domain of Shank2 was performed using the Swissmodel server (swissmodel.expasy.org), using pdb entry 5IZU as a template.
A construct coding for mCherry-tagged human Shank2a was obtained from Dr. Simone Berkel (Heidelberg, Germany) . The Shank2a cDNA was cloned into the pHAGE-GFP vector for transfecting neurons. A rat cDNA for CortBP1 (Shank2b), donated by Dr. J. Thomas Parsons (University of Virginia) was cloned into pEGFP-C2, leading to expression of N-terminally GFP-tagged Shank2b. cDNA coding for GKAP was obtained from Prof. Stefan Kindler (UKE, Hamburg). Mutations were introduced using the QuikChange II site-directed mutagenesis kit (Agilent). cDNA coding for the 50 C-terminal residues of GKAP was amplified by PCR with appropriate primers and subcloned into BamHI/EcoRI sites of pGEX-4T2, allowing for expression as a GST fusion. For expression of the Shank2-SAM domain, cDNA coding for residues T1780–R1849 was cloned into pET-SUMO (Thermo-Fisher), allowing for expression of a SUMO-SAM fusion with an N-terminal His6-tag. A cDNA-fragment coding for SH3 to PDZ domains of Shank2 (R520–D727) was cloned into pET-SUMO. shRNA constructs were generated in pSuper based on constructs used by Berkel et al.  carrying target sequences GGATAAACCGGAAGAGAT (shShank2#1) and GGAATTGAGCAAAGAGATT (shShank2#2). A construct coding for rat Homer1b with an N-terminal GFP-tag in pEGFP-C1 was described .
Cell culture and transient transfection
293T HEK (human embryonic kidney; ATCC) cells were maintained in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum and 1% penicillin/streptomycin. Cells were transiently transfected with Turbofect Transfection Reagent (Thermo Scientific) according to the manufacturer’s instructions. Cells were regularly monitored for absence of mycoplasma.
Immunoprecipitation and pulldown experiments from transfected cells
Transfected cells were lysed in immunoprecipitation (IP) buffer (50 mM Tris-HCl, pH 8, 120 mM NaCl, 0.5% NP40, 1 mM EDTA), followed by centrifugation at 20,000 × g for 15 min at 4 °C. Immunoprecipitation of GFP-tagged proteins from supernatants was performed using 20 μl of GFP-trap beads (Chromotek, Munich, Germany). For pulldown assays using the extended PDZ ligand of GKAP, 50 μl of GST-GKAP fusion protein coupled to glutathione sepharose beads were used. Cell lysates were incubated with the respective beads for 2 h at 4 °C on a rotator. After washing, precipitates and input samples were processed for Western blotting.
SDS PAGE and Western blot
Proteins were separated on SDS-PAGE under denaturing conditions and transferred to nitrocellulose membrane using a MINI PROTEAN IITM system (Bio-Rad). Membranes were blocked with 5% milk powder/TBS-T and incubated with the primary antibodies overnight at 4 °C, followed by washing in TBS-T and then HRP-linked secondary antibodies at room temperature for 1 h. Membranes were scanned using a ChemiDocTM MP Imaging System (Bio-Rad) and images were processed and further analysed using Image Lab Software (Bio-Rad).
GST fusion proteins were expressed in BL21(DE3) cells (Thermo-Fisher) and purified from bacterial lysates in STE buffer, using glutathione sepharose beads. Proteins were left on the beads and after several washing steps used for pulldown assays. His6-SUMO-tagged fusion proteins were expressed in BL21(DE3) cells and purified from bacterial lysates prepared in native lysis buffer (50 mM NaH2PO4, 500 mM NaCl, pH 8.0) using Ni–NTA agarose (Qiagen, Hilden, Germany). Proteins were eluted from beads with 250 mM imidazole in lysis buffer and immediately applied to G-25 columns (GE Healthcare), followed by elution in 0.5 M NaCl, 20 mM Tris/HCl pH 7.5 (for Zn2+ aggregation assays) or 150 mM NaCl, 50 mM Tris-HCl; pH 8.0 (for cleavage with SUMO protease). For protease cleavage, 1 mM DTT and 50 μl SUMO protease (Thermo-Fisher) were added to a total of 10 ml solution with a protein concentration of about 1 mg/ml. After digestion at 4 °C overnight, the His6-tagged SUMO part of the fusion protein, as well as His6-tagged SUMO protease, were removed by a second incubation with Ni-NTA Agarose. Efficiency of all protein purifications was verified by SDS-PAGE, followed by Coomassie staining. Protein concentrations were determined by Bradford assay, using BSA as a standard.
Isothermal titration calorimetry (ITC)
Synthetic peptides corresponding to the complete PDZ ligands of GKAP (sequence: NH2-ADSIEIYIPEAQTRL-COOH) and CIRL1 (NH2-PGPDGDGQMQLVTSL-COOH) were obtained from Genscript (Leiden, The Netherlands). Affinities between WT and mutant Shank2 protein fragments (His6-SUMO-tagged SH3 to PDZ domains) and the peptides were measured by ITC using a MicroCal PEAQ-ITC instrument (Malvern Panalytical). All titrations were performed at 25 °C with protein concentrations between 20 and 30 µM (WT: 20 µM, G643R: 22 µM, N690S: 30 µM, S610Y: 25 µM, V717F: 27 µM) in the sample cell. The peptide concentration in the syringe was 200 µM (1 mM for the G643R variant). All solutions contained the same buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA). For each titration, one initial injection of 0.4 µl (0.8 s injection time) followed by 12 injections with 3 µl each (6 s injection duration) with a spacing of 300 s between injections and a stirring speed of 500 rpm was done. All thermograms were baseline corrected and integrated using NITPIC . SEDPHAT  was used for fitting a 1:1 binding model and GUSSI  for generating the final plots.
Zn2+-dependent aggregation assays
Purified SAM domains were treated with different concentrations of Zn2+. 20 µl drops were placed on microscopy slides and the formation of aggregates was observed under the light microscope for 5 to 15 min. Clusters were photographed using a standard digital camera. For turbidity assays, isolated SAM domains were mixed in wells of a 96-well plate with varying concentrations of Zn2+ in a total volume of 200 µl. Absorbance at 350 nm was determined at different time points using Epoch™ Multi-Volume Spectrophotometer System .
Protein crystallization and crystal structure determination
Crystals of the Shank2-SAM WT and mutant (L1800W) were obtained using the vapor diffusion method and sitting drop technique. SAM-WT crystals grew after 2 weeks from a crystallization condition containing 0.1 M Bis-Tris pH 5.5 and 0.3 M of Mg-formate and a protein concentration of 7.5 mg/ml. The mutant crystals appeared in 0.1 M Bis-Tris pH 5.5 and 26% polyethylene glycol monomethyl ether 2000 (PEG 2000MME), with a protein concentration of 11 mg/ml, after 48 h and took 14 days to grow to suitable size. X-ray data collected at the EMBL PETRA III beamlines (P14, P13) in Hamburg showed that SAM-WT and SAM-L1800W crystals diffracted to 2.1 Å; and 1.95 Å, respectively.
X-ray data sets were processed and scaled using XDS  and AIMLESS , respectively. Both crystal structures, SAM-WT and SAM-L1800W, were solved by the molecular replacement method, with program MOLREP , using as a search model the homologous structure of Shank3-SAM domain (PDBID 2f44)  for SAM-WT, and the refined structure of SAM-WT for the L1800W mutant structure. Structure refinement proceeded using REFMAC  or Phenix  programs and model building was done using COOT . CCP4i2  and ccp4cloud (https://cloud.ccp4.ac.uk/) were used during structure solution and refinement. Both structures were checked periodically using the PDB_redo server (https://pdb-redo.eu/)  and validated with MOLPROBITY . The final structures were deposited in the Protein data bank (PDB, https://www.ebi.ac.uk/pdbe). Data collection and Refinement statistics are listed in Table S2. Figures were drawn with PyMOL (https://pymol.org/2/).
Dynamic light scattering (DLS)
Measurements were performed using DynaPro Nanostar (Wyatt Technology Corporation). Data were processed using Dynamics v.7 software. 50 μM protein and 50 µM Zn2+ were mixed and incubated for 1 h at room temperature. Samples were filtered through 0.22 μm centrifugal filters (Millipore). The acquisition time was 3 s with a total of 30 acquisitions.
Primary cultures of hippocampal neurons were prepared from Rattus norvegicus embryonic day-18 rats of both sexes (Envigo), as described . All animal experiments were approved by, and conducted in accordance with, the guidelines of the Animal Welfare Committee of the University Medical Center Hamburg-Eppendorf (Hamburg, Germany) under permission number Org766.
Neuron culture and transfection
After dissection of hippocampal tissue, neurons were extracted by enzymatic digestion and mechanical dissociation. Dissociated neurons were plated on glass coverslips and maintained in Neurobasal medium supplemented with 2% B27, 1% Glutamax and 1% Penicillin/Streptomycin. Transfection of neurons was performed at DIV7 using the calcium phosphate method. For Zn2+ treatment, 10 µM Zn2+ was added to transfected neurons (DIV8).
Neurons (DIV10; DIV11 after Zn2+ treatment; DIV14 for Shank3 staining) were fixed with 4% paraformaldehyde in PBS for 15 min and permeabilised with 0.1% Triton X-100 in PBS for 5 min. After 1 h blocking with 10% horse serum in PBS, cells were incubated with corresponding antibodies overnight followed by washing and then 1 h of incubation with Alexa Fluor coupled secondary antibodies. The coverslips were mounted onto glass microscopic slides using ProLongTM Diamond Antifade mounting medium.
Confocal images were acquired with a Leica Sp5 confocal microscope using a 63x objective. Super-resolution imaging was performed using a STED microscope from Abberior. The STED images were acquired with the pixel size of 20 nm and the scanning area of ~15 µm. Quantitative analysis for images was performed using ImageJ. Primary dendrites were counted at a ring within 10 µm distance from the soma. The counting of clusters along dendritic branches was performed using the Multi-Point tool of ImageJ. The distance between the head of a dendritic spine and the dendritic shaft was measured using ImageJ’s straight line tool.
The following primary antibodies were used: mouse anti-GFP (Covance MMS-118P-500, RRID: AB_291290; WB: 1:3000); rat anti-RFP (Chromotek 5F8, WB: 1:1000); rabbit anti-GFP (Abcam AB6556; ICC: 1:500); chicken anti-MAP2 (Antibodies-Online ABIN361345, ICC: 1:1000); mouse anti PSD-95 (Thermo-Fisher MA1-046; ICC: 1:500); guinea pig anti-Shank3 (Synaptic Systems 162 304; ICC 1:1000); rabbit anti-Shank2 (Sigma-Aldrich HPA008174; ICC 1:250); rabbit anti-VGlut (Synaptic Systems; ICC: 1:2000). HRP-labeled goat secondary antibodies were from Jackson ImmunoResearch and used for WB at 1:2500 dilution. For ICC, Alexa 405 goat anti-chicken IgG (abcam; ab175675 at 1:1000 dilution), Cy3 goat anti-rb IgG (Dianova; at 1:1000 dilution). Abberior STAR RED goat anti-mouse IgG and Abberior STAR RED goat anti-rabbit IgG (Abberior) were used at 1:1000 dilution.
Recording of miniature excitatory postsynaptic currents
The synaptic activity of transfected primary hippocampal neurons was recorded at DIV 9-10, 2–3 days after transfection. Throughout the experiments, cells were superfused with ACSF (artificial cerebro spinal fluid) of following composition (in mM): NaCl, 120; NaHCO3, 26; NaH2PO4, 1; KCl, 2.5; Glucose, 2.8; CaCl2, 2; MgCl2, 1. The whole cell configuration was employed using patch pipettes with a resistance of 3–6 MΩ. Recordings were made using MultiClamp 700B and 700A amplifiers and Clampex 10.7 software (both Molecular Devices, LLC. San Jose, CA, USA). Recordings were digitized at 10 kHz and filtered (Bessel filter, 2 kHz). The pipette solution contained (in mM): CsCl, 120; Hepes, 10; EGTA, 0.2; MgCl2, 2; CaCl2, 0.075; Na-ATP, 2; Na-GTP, 0.5; 4-AP, 5; TEA-Cl, 20. To block voltage gated sodium channels and GABAA receptors, 0.5 µM TTX and 5 µM gabazine were added to the ACSF. Cells were held at −65 mV in voltage clamp recording. Series resistance (Rseries) was monitored during the recording and cells exceeding 20 MΩ and/or a change of 20% in Rseries were excluded from the analysis. MiniAnalysis software (Synaptosoft) was used to analyze frequency and amplitude of spontaneous synaptic events (mEPSC) which were collected over a 2 min period. The automated threshold function based on noise detection included in the software was applied before detection of events.
Evaluation of data
Sample size was chosen in each case based on previous experience with the relevant technique [28, 44,45,46,47]. No samples were excluded. No randomization was used. For confocal analysis, samples were blinded for quantitative evaluation of measurements. Normal distribution of data, and statistical significance was determined using Prism8 software (GraphPad, San Diego, CA). Data were analysed by Student’s t-test or one-way ANOVA with post hoc Dunnett’s test or two-way ANOVA with post hoc Sidac’s and Dunnett’s test for normal distributed data. Otherwise, the Kruskal–Wallis test was used. For mEPSC analysis, the cumulative probability of inter-event intervals was plotted and tested for significant differences (Kolmogorov–Smirnov test) using OriginPRO software (version 2021b, Origin Lab Corp., Northampton, MA, USA). All data are presented as mean ± SD.
Missense mutations in SHANK2 cause a severe neurodevelopmental disorder
We identified a 17-year-old boy who was referred to the hospital due to intellectual disability (ID), autism spectrum disorder (ASD) and epilepsy (see Supplementary Data, and Table S1 for clinical description). Trio whole-exome analysis discovered a de novo missense variant c.1927G>C (p.Gly643Arg) in SHANK2 (NM_012309.5; Fig. 1a, b). This variant was found to be deleterious using predictions programs such as CADD ; it is absent from catalogs of human genetic variation (i.e., the GnoMAD database). Using the Genematcher portal , we identified one further individual with developmental delay, mild intellectual disability, microcephaly, behavioral abnormalities and attention deficit hyperactivity disorder. Again, a de novo missense variant (c.5399T>G, p.L1800W) in SHANK2 was found in the patient.
The p.G643R mutation disrupts binding of Shank2 to GKAP
Shank PDZ domains are type I PDZ domains. PDZ type I ligands carry a C-terminal X − S/T − X − Φ –COO− motif, where X is variable, and Φ hydrophobic. In GKAP, Φ is leucine (L(0) in PDZ terminology), which together with threonine at the −2 position constitutes the main specificity determinants for type I PDZ domains [3, 4]. In addition, an extended sequence N-terminal to the PDZ domain (corresponding to residues 597–628 in Shank2) adds to binding affinity and specificity as it binds to an extended surface of the PDZ ligand . The extended binding site is provided by a second Shank molecule, indicating that a dimer of Shank proteins binds to two GKAP molecules. All 15 C-terminal amino acids of GKAP are required for high affinity interaction with Shank3 . Homology modeling in Fig. 1c shows that also the Shank2/GKAP interaction uses the same extended interface, such that all 15 C-terminal amino acids of GKAP bind to the extended binding site of Shank2.
Upon homology modeling of WT and mutant Shank2 based on the Shank3/GKAP structure  we observed that known mutations affect residues in the extended PDZ domain (S610Y) or in regions on the backside of the PDZ domain, facing away from the ligand (N690S, V717F; Fig. 1c). In contrast, G643 is in a central position in the peptide binding groove. G643 is highly conserved in type I PDZ domains (Fig. 1b). In structures of PDZ domain/ligand complexes [51, 52], a glycine at this position anchors a conserved histidine (H698 in Shank2; Fig. 1d) through a hydrogen bond of its carbonyl group with N-1 of H698. N-2 of H698 is involved in hydrogen bonding to the OH-group of Thr at the −2 position of the PDZ ligand, the major determinant of specificity for type I PDZ domain interactions (Fig. 1d). Replacement of Gly643 with Arg introduces a bulky side chain at this position, which clashes with His698 (Fig. 1d). Thus, instead of supporting the correct positioning of H698, Arg643 pushes away His698, thereby distorting the binding site for the GKAP PDZ ligand.
We performed a GST pulldown using the Shank2a isoform containing the extended binding site, and a GST fusion protein containing the complete GKAP PDZ ligand also including the extended binding region in GKAP. We included PDZ domain variants identified in individuals with schizophrenia , i.e., p.S610Y (in the extended binding site on Shank2) and p.N690S. Here, the p.G643R variant almost completely disrupts the binding of Shank2 to GKAP through the PDZ domain, whereas the two previously reported mutations only slightly, and non-significantly affected binding (Fig. 1e, f). To obtain more precise data, we also generated His6-SUMO tagged fusion proteins encompassing SH3 and PDZ domains of Shank2 (Fig. S1). We measured binding to a synthetic peptide containing the last 15 amino acids of GKAP/SAPAP1, using isothermal titration calorimetry (ITC). Here, the S610Y, N690S  and V717F  mutants elicited moderate to no reductions in affinity, whereas G643R reduced the affinity more than 70 fold (Figs. 1g, h, S2).
We also performed ITC experiments with a peptide corresponding to the C-terminal PDZ ligand of CIRL1/latrophilin . For this ligand we detected an about 40-fold reduced affinity for the wild type protein, in agreement with previous observations that GKAP is the partner with the highest affinity for Shank PDZ domains. Importantly, binding to G643R mutant Shank2 was not detectable in this assay (Fig. S3), clearly demonstrating that the mutation destroys the core function of the PDZ domain of Shank2.
The p.L1800W mutation in SHANK2 interferes with the formation of Shank2 oligomers
Zn2+-dependent formation of homo/hetero-oligomers of Shank SAM domains is thought to be fundamental for PSD formation [1, 3, 13]. L1800 is conserved in SAM domains of all three Shank proteins (Fig. 2a). We analysed the capacity of WT and L1800W mutant Shank2 to interact with another Shank2 molecule in a coimmunoprecipitation experiment. Cells coexpressing differently tagged Shank2 proteins (GFP- and mCherry-tagged) were lysed and subjected to immunoprecipitation using the GFP-trap matrix. Here, the p.L1800W variant negatively affects Shank2-Shank2 interactions, as coprecipitation of mCherry-tagged Shank is reduced by the mutation (Fig. 2b, c). It should be noted that this experiment was performed in buffer containing 1 mM EDTA, likely to sequester any Zn2+ from cell lysates. However, the Shank2 and Shank3 Zn2+ binding sites are of high affinity, and it appears possible that some Zn2+ remains attached to SAM domains during the procedure. The residual interaction observed here may also be caused by other domains of Shank2, not only the SAM domain.
Both mutations identified here do not affect binding to Homer, as determined in coexpression/coimmunprecipitation assays, further confirming the specific role of G643 for the PDZ domain, and L1800 for the SAM domain (Fig. S4).
p.L1800W causes a delayed Zn2+-dependent polymerization of SAM domains
We purified His6-SUMO-tagged SAM domains (Fig. S1) and established in vitro polymerization assays. WT or L1800W mutant proteins (at 10 µM concentration) were treated with Zn2+, and the resulting samples were viewed under a microscope at 5 min after adding Zn2+ (Fig. 2d). For the WT, we readily observed large (>5 µm) clusters shortly after adding 10 µM Zn2+ whereas at this concentration the L1800W solution remained clear, without cluster formation. At higher concentrations of Zn2+ (30 µM), and also at longer incubation times with 10 µM Zn2+, the p.L1800W mutant protein also started to form clusters. No clusters were seen at a Zn2+ concentration of 3 µM for both variants. Higher magnification pictures at the 10 µM/5 min condition showed huge irregular clusters for the WT SAM domain, whereas multiple, but rather small aggregates appear for the p.L1800W mutant protein (Fig. 2d, lower panel).
For quantitation, we measured absorbance of SAM-domain/Zn2+ solutions as a function of time and Zn2+ concentration at 350 nm. Here the p.L1800W variant required higher concentrations of Zn2+ for efficient cluster formation, with an EC50 of 4.8 µM for the WT, and 9 µM for the mutant. The curve for Zn2+ concentration dependence was extremely steep for both variants, with no effect seen at the lower concentration of 2 µM Zn2+. Nonlinear regression analysis gave Hill coefficients of 6.5 (WT) and 8.2 (L1800W), pointing to high cooperativity of Zn2+-dependent aggregation (Fig. 2e).
We also kept Zn2+ constant but varied the protein concentration. Absorbance reached a maximum when concentrations of both protein and Zn2+ were equal, clearly indicating that a stoichiometry of one Zn2+ ion per protein molecule is required for efficient cluster formation (Fig. 2f). A striking difference between WT and mutant was observed in the kinetics of aggregate formation. The WT SAM domain formed aggregates very rapidly, with half of the maximum absorbance already reached at the initial 10 s time point after adding Zn2+. In contrast, the mutant showed a lag phase of 30–40 s of no aggregation, before starting an almost exponential increase in absorbance which reaches saturation after about 300–400 s (compared to WT which approaches saturation much earlier). No aggregation was observed for the His6-SUMO-SH3-PDZ fusion, used as a negative control here (Fig. 2g). These data indicate that the rapid, cooperative aggregation of SAM domains in the presence of Zn2+ is remarkably slowed down in the mutant. Only after an initial, slow polymerization in p.L1800W SAM domains, the mutant can begin with rapid, exponential growth of clusters.
The p.L1800W variant alters the Zn2+ binding site of Shank2
We obtained crystals of Shank2-SAM domains after cleaving off the His-SUMO tag (Fig. S5); differences in Zn2+-dependent aggregation were verified for the isolated domains by dynamic light scattering (DLS; Fig. S6). Upon solving the structure of the WT, we observed high similarity between the Shank2-SAM domain, and the structure of M56E mutant Shank3-SAM domain (see Fig. 3a–c) . Differences were observed in the region of the Zn2+ binding site, as the Shank3 crystals had been soaked with Zn2+, and the site was fully occupied. Though no Zn2+ was added to Shank2 crystals, we observed that about 30% of the Zn2+ sites were occupied. Apparently some Zn2+ binding had been maintained during purification. Due to the incomplete occupancy, the tetrahedral coordination of the Zn2+ ion made by His1803, His1835, a chloride ion and Glu1802 was somewhat distorted and incomplete (Fig. 3b). Nevertheless, the WT SAM domain crystallized in the same space group, showing the same crystal packing as reported for Shank3. Importantly, this packing arrangement allowed for the formation of helical polymers of SAM domains, and the side-by-side alignment of these helices, leading to larger sheets of polymerized SAM domains (Fig. 3c). As reported by , contacts via the intrahelical interface can be distinguished from the additional inter-polymer interface. Both interfaces are supported by the Zn2+ binding site which is localized at the contact site between these two interfaces. In the electron density map (Fig. S7), the N-terminal Thr residue (T1780) of a neighboring SAM domain is visible; this is in fact a SAM domain from the adjacent fiber, representing an interhelical contact (see below).
On the other hand, we could not readily generate crystals from the L1800W mutant SAM domain. After one round of optimization, crystals were obtained that diffracted to 1.95 Å. Structural comparison between the crystals structures of WT and of the L1800W mutant SAM domains shows that the bulky side chain of the Trp induces a shift of the C-terminal helix, locating it further away from the Zn2+ cluster (Fig. 3d, e). This shift places H1835 about 2.0 Å away from the position observed for SAM WT. Furthermore, H1835 adopts a different conformation for its side chain, as well as the side chain of R1832. As a result, the Zn2+ binding site is altered or possibly destroyed. It will be interesting to structurally analyse larger C-terminal fragments of Shank2, to determine whether other parts of the protein affect polymerization. However, we found larger fragments difficult to purify and crystallize (not shown).
The crystal packing of the mutant SAM domain was remarkably different from the WT, as no helical sheets similar to those seen in Fig. 3c for the WT were obtained with the mutant. A closer inspection of the interactions of SAM domains within the crystals showed that the WT domain established several interactions with the neighboring molecules, which are responsible for the formation of helical fibers (Fig. 3f; see also Table S3). In addition, we observed interactions to SAM domains in the neighboring helix. These are needed for the side-by-side stacking of helices, which is a hallmark of Shank SAM domains . While the intrahelical contacts are partially maintained in the L1800W mutant, the interhelical contacts are completely lost as no neighboring molecule is observed at the appropriate position in the crystal (Fig. 3g and Table S3).
SHANK2 mutations interfere with postsynaptic targeting
We investigated the effect of both mutations on the postsynaptic localization of Shank2 in primary cultured hippocampal neurons. The endogenous rat Shank2 was knocked down using Shank2 shRNA (ShShank2) constructs described by . This approach targets almost exclusively excitatory, glutamatergic neurons, as only a low percentage (about 6%) of neurons in this type of culture is inhibitory . Efficient knockdown was verified on a Western Blot level in transfected 293T cells, and in primary cultured neurons by immunocytochemistry (Fig. S8). The knockdown construct was coexpressed with GFP-tagged human SHANK2 variants, which are not susceptible to the shRNA due to sequence divergence of the shRNA target (Fig. S8). Transfected neurons were initially analysed by confocal microscopy (Fig. 4a). We observed that neuronal morphology (i.e., the number of primary dendrites and the length of dendritic spines) were not significantly altered under any of the conditions tested here (Fig. S9). We found that the number of dendritic GFP-Shank2-positive clusters per dendrite length was reduced by the L1800W SAM domain mutation, but not by the G643R PDZ mutation (Fig. 4b). Interestingly, both overexpressed variants of Shank2 showed no effect on the density of PSD-95 clusters along the dendrite (Fig. 4c), whereas the L1800W variant showed a decreased density of presynaptic clusters of VGlut which were positive for Shank2 (Fig. 4d). Importantly, when we measured the ratio of cluster/spine fluorescence intensity versus the intensity in the adjacent dendritic shaft, we saw a significant reduction in this ratio for both mutants when compared to the wild type (Fig. 4e). Our data indicate that both the PDZ domain and the C-terminal SAM domain contribute to the targeting of Shank2 to the postsynaptic sites and mutations in both functional domains may affect the proper targeting of this protein to postsynaptic sites.
As Shank3 can perform many of the same interactions and functions as Shank2, Shank3 might in some way compensate for non-functional Shank2. We analysed cells expressing WT and mutant protein for changes in the postsynaptic targeting of the endogenous Shank3 protein. Indeed, we observed an increase in the number of dendritic Shank3 clusters in neurons expressing G643R-Shank2 (Fig. S10).
We investigated whether the deficits of Shank2 mutants in forming postsynaptic clusters can be rescued by a higher Zn2+ concentration. Increasing Zn2+ concentration for a short period of time (1 h, additional 10 µM Zn2+) had no apparent effect on Shank2 clustering (data not shown). In contrast, long term treatment of cultures with additional Zn2+ significantly increased the number of Shank2 clusters for WT Shank2, as well as the number of PSD-95-positive Shank2 clusters and the spine to shaft ratio. For the G643R mutant, similar changes were observed in the number of clusters, and, to a lesser extent, in the spine/shaft ratio. For the L1800W variant, we observed only a rather weak effect of Zn2+ treatment for all three parameters, with no significant change in the number of PSD-95 positive clusters (Fig. 4f–i).
SHANK2 mutations interfere with the formation of postsynaptic nanoclusters
The postsynaptic localization of scaffold proteins is not uniform, but occurs in so-called nanoclusters; several of these ∼80 nm structures may be distinguished in a single spine head [14, 15]. Determinants which are responsible for targeting of Shank or other postsynaptic proteins to these nanoclusters are unknown. We combined confocal microscopy and 2D STED imaging on Shank2-positive clusters from transfected neurons (Fig. 5a). Clusters were identified in the confocal mode, and then further resolved by STED microscopy. We routinely observed multiple subclusters in the STED images. Although the size of clusters was similar in all three conditions (Fig. 5b), for the p.G643R variant, we observed that the size of subclusters is increased in comparison to subclusters containing the WT Shank2 (Fig. 5c). For both mutants, the number of the subclusters was significantly decreased (Fig. 5d), suggesting that the compaction of Shank2 protein into nanoclusters is reduced by the mutations (Fig. 5c, d).
In a second set of experiments, we focused our analysis on nanoclusters of PSD-95, which is indirectly associated with Shank2 via GKAP. In GFP-Shank2-positive dendritic spines, we observed that PSD-95 nanoclusters were altered in the same manner as the Shank2 clusters, as the size of nanoclusters was increased for neurons expressing the p.G643R variant, and the number of nanoclusters was reduced for both variants when compared to the wild type (Fig. 5e–h). On the other hand, STED microscopy of presynaptic VGlut clusters did not reveal any differences between cultures expressing the different Shank2 variants (Fig. S11).
To assess the effects of Shank2 mutants on synaptic function, we recorded miniature excitatory postsynaptic currents (mEPSCs) in primary cultured hippocampal neurons. In neurons expressing the p.L1800W variant (n = 25), the inter-event interval of mEPSCs was significantly increased compared to wild type (n = 36), consistent with the reduction in the number of functional synaptic sites, as observed in Fig. 4b, d. The inter-event interval of mEPSCs was slightly but significantly decreased in neurons expressing the p.G643R variant (n = 18) (Fig. 5i, j). In addition, the mean mEPSC amplitude was significantly larger for the p.G643R variant but unaltered for the p.L1800W variant (Fig. 5k).
Whereas many mutations in SHANK genes have been described in individuals with neurodevelopmental disorders , little is known about the functional effects of missense mutations on the molecular properties of the encoded proteins. We describe two patients with de novo missense variants in SHANK2 affected by a severe neurodevelopmental disorder, comprising moderate intellectual disability, delayed acquisition of motor and language skills, but also seizures (patient 1) and microcephaly (patient 2). Patients appear to be more severely affected than those carrying heterozygous loss-of-function variants, occurring e.g., trough frameshift or early stop mutations . The variants alter two domains which are of central relevance for Shank protein function, i.e., the PDZ and SAM domains [3, 13]. To our knowledge these are the first de novo variants in these two domains which show a clear functional deficit for either domain, detectable in structural, biochemical as well as cell biological assays.
Three additional SHANK2 variants in the PDZ domain had been observed in patients (p.V717F in an autism case, p.S610Y and p.N690S in schizophrenia patients [20, 23]). As the effects of these variants on interaction with GKAP had not been analysed, we included them here in our binding assays. GKAP is believed to be the most relevant partner of Shank PDZ domains, as it uses an extended interface with Shank proteins for high affinity interaction . The p.G643R variant almost eliminates binding of GKAP to the PDZ domain of Shank2. G643 is highly conserved within type I PDZ domains, and our molecular modeling as well as published 3D structures suggest that the large Arg residue at position 643 destroys one of the major hallmarks of type I PDZ domain interactions, i.e., the selectivity for the obligatory Ser/Thr residue at the (-2) position of the ligand. For the S610Y and V717F variants, a moderate reduction in binding affinity was observed, consistent with the localization of S610 and V717 outside the immediate ligand binding site (Fig. 1). The reduced affinity of the S610Y variant supports the relevance of the extended PDZ domain. It should be noted that the phenotype of the patient reported here is more severe, with a more general neurodevelopmental delay compared to the autism (V717F) and schizophrenia (S610Y) phenotypes caused by the other mutations [20, 23]. The lack of effect of the N690S variant questions its pathogenicity.
The p.L1800W variant is the first missense variant affecting the function of Shank SAM domains. Polymerization into helical structures, as well as the side-by-side alignment of these helices into sheet-like structures as observed for Shank3 is dependent on the presence of Zn2+ . By varying the concentration of Zn2+ in microscopic and photometric aggregation assays, we observed here that aggregation does not increase in a linear manner with increasing Zn2+ concentrations, but instead shows an S-shaped curve reminiscent of the oxygen binding curve of hemoglobin. Hill coefficients between 6 and 8 clearly indicate that Shank2-SAM domain aggregation is a highly cooperative process. This may have important therapeutic consequences, as very small increases in the available postsynaptic Zn2+ concentration (e.g., through increased dietary uptake) may have a profound effect on the assembly of postsynaptic Shank clusters (as observed recently, ). We found that this cooperative process is severely delayed by the p.L1800W mutation. Our structural analysis of WT and mutant Shank2-SAM domains provides a molecular explanation for these findings. Replacement of L1800 with a large, aromatic residue leads to an outside movement of the carboxy-terminal helix, thereby detaching His1835 from the tetrahedral coordination sphere of the Zn2+ ion. As a result, Zn2+ affinity is reduced to the effect that no Zn2+ is found in the mutant protein, whereas WT SAM domain keeps partially attached to its bound Zn2+ during the purification and crystallization procedure. Though Zn2+ binding is apparently still possible, the conformational changes disrupt several interactions with other SAM domains in the polymeric assembly process. This is especially true for the contact between helical fibers of SAM domains, but not within these helices; thus, the mutation affects a Shank-specific feature of SAM domains, the ability to form larger sheets through side-by side stacking of the helices described by  and also observed here for WT Shank2. This deficit in the two-dimensional packing of SAM domains is likely to be responsible for the delayed polymerization which was observed in our in vitro aggregation assays (see Fig. S12 for a model).
Functional studies were performed in primary cultured hippocampal neurons, which endogenously express all three Shank isoforms. We expressed GFP-tagged Shank2 variants together with a knockdown plasmid for the endogenous protein, to avoid “Shank overload”. While it is difficult to precisely measure the total amount of Shank2, we think that this creates a homozygous situation for the expressed Shank2 mutants. We felt that this is necessary to observe a robust phenotype. In fact, functional studies in model organisms (e.g., in Shank ko mice) usually rely on a homozygous situation in order to detect a phenotype [57,58,59], despite the fact that SHANK mutations in human patients are always heterozygous. In two recent studies, even double knockout mouse lines (deleting a total of four Shank allels) have been analysed to more clearly assess the function of Shank proteins in synaptic function and autism pathology [60, 61].
Upon expression in neurons, both mutations reduced the efficiency of targeting of the Shank2 protein to postsynaptic clusters. Previous work has led to divergent results regarding the role of Shank domains for synaptic targeting. Thus, targeting of Shank1 depends on the PDZ domain , and therefore, on the interaction with GKAP, whereas Shank2 and Shank3 require an intact C-terminal synaptic targeting motif which includes a functional SAM domain . Our work suggests an intermediate view for Shank2, as both intact PDZ and SAM domains contribute to efficient targeting to postsynaptic sites. Differences between our experiments and previous studies may originate from the use of CMV-promoter based constructs which drive high levels of expression. We have used here expression constructs based on the EF1α promoter, which may bring about more physiological expression levels.
Addition of Zn2+ to neuronal cultures increases postsynaptic clustering of Shank2 and Shank3 . We estimate the physiological total Zn2+ concentration in neuronal cultures to be in the lower µM range, whereas the free Zn2+ concentration is believed to be highly variable. By adding further Zn2+, free Zn2+ levels are likely to rise. In our hands, endogenous (e.g., Fig. S10) and overexpressed Shank proteins are efficiently clustered and targeted to postsynaptic sites [28, 45], suggesting that this concentration of Zn2+ is sufficient for the amount of Shank present in dendrites. However, by adding 10 µM Zn2+ to cultures for 3.5 days, we observed increased formation of PSD-95 positive, postsynaptic clusters for WT and G643R mutant Shank2, but not for the L1800W mutant. Also the increase in spine targeting of the protein was less pronounced for the SAM domain mutant, further confirming that Zn2+ dependent polymerization of the Shank2-SAM domain mediates the effect of Zn2+ on synapse formation. This is in agreement with in vivo data, showing that limited availability of Zn2+ during mouse development impairs targeting of Shank proteins to synaptic sites, and is associated with the development of autism-like symptoms [65, 66].
Reduced targeting to postsynaptic sites coincides for both mutants with changes in the formation of postsynaptic nanoclusters which are responsible for the tight spatial association of the presynaptic neurotransmitter release machinery with postsynaptic AMPA receptors [14, 15]. So far it is unknown how formation and the correct positioning of nanoclusters is achieved on a molecular level. Recent in vitro work has shown that interactions between scaffolds PSD-95, GKAP, Shank and Homer drive a liquid-liquid phase transition, which is likely to be involved in postsynaptic clustering and nanocluster formation . The PDZ-mediated GKAP-Shank interaction, as well as the SAM domain mediated polymerization of Shank proteins feature prominently in this process. It is likely that these interactions first serve to bring the postsynaptic proteins into close proximity; in a next step, the large intrinsically disordered segments of all three Shank proteins are likely to perform the phase transition which then creates the really “dense” nanoclusters observed by super-resolution microscopy. Thus, the mutations identified here interfere with the compaction of postsynaptic clusters, by affecting two of the most important interactions mediated by Shank proteins. We would assume that GKAP nanoclusters are affected in a similar manner; however, we are currently not aware of a suitable antibody to analyse this. Importantly, we show that the changes in nanoclusters extend throughout the PSD, as PSD-95 clusters are also affected in a similar manner as Shank2 clusters by both mutations (Fig. 5). This confirms that Shank multimerization, and formation of the Shank/GKAP/PSD-95 complex, are central aspects of nanocluster formation which are severely disrupted by the mutations found in our patients.
Both mutations analysed here are associated with altered synaptic transmission (Fig. 5). mEPSCs are less frequent for the L1800W mutant, in agreement with the reduced number of functional synapses (VGlut-positive Shank2 clusters) observed upon expression of this variant. In case of the PDZ domain mutant, in fact we see a slight increase in the number of mEPSCs, coinciding with an increase in signal amplitude. These data indicate that there is no clear correlation between nanocluster formation and strength of postsynaptic currents. It should be noted here that we actually observed larger nanoclusters in neurons expressing this variant (Fig. 5), and that there was a compensatory response by Shank3 in these neurons (Fig. S10). Postsynaptic content of Shank3 was also increased in the Shank2 ko mice, indicating that Shank3 may take over as interaction partner for the GKAP C-terminus in the absence of Shank2; no increase for Shank1 was observed in these mice .
We believe that, e.g., upon introduction into the mouse genome, these mutations will provide an important opportunity to study the relevance of nanocluster formation for synaptic signaling and synaptic plasticity. These aspects cannot easily be addressed in a cultured neuron system. Furthermore, it may be interesting to vary the Zn2+ concentration before or during electrophysiological measurements.
As the patients described here appear to be more severely affected than those carrying heterozygous loss-of-function variants , our data suggest that nanocluster compaction is indeed a central aspect of Shank2 function. Furthermore, our data suggest a dominant pathomechanism, where the mutant Shank2 allel is dominant over the WT allel, and possibly also over the other two SHANK genes which send their gene products to the same postsynaptic sites. Our experience with other genes causing neurodevelopmental disorders shows that often missense variants cause a more severe phenotype than loss-of-function variants. This happens when variants do not disrupt folding and overall abundance of the gene product, but rather interfere with one specific and important molecular interaction while leaving others intact [68,69,70]. For Shank2 variants described here, other interactions outside PDZ (for p.G643R) and SAM (for p.L1800W) domains are not affected; targeting of the mutant protein to postsynaptic sites is reduced but not abolished. As Shank proteins in the PSD are part of a dense network of protein interactions, this suggests that this network is disrupted at one particular position (the PDZ-GKAP contact, or the interface between two helices of SAM domains), causing a disrupted molecular pattern. Due to the tight incorporation of Shank2 (mutant or WT) into the PSD complex, this cannot be fixed by the presence of other intact Shank proteins, such as Shank3 which is mostly equivalent to Shank2 in its protein interactions, and which is increased in abundance at postsynaptic sites upon introducing a Shank2 mutation (Fig. S10). Cotransfection of WT and mutant Shank2 (e.g., with two different tags) upon a knockdown background would be the ideal experiment to experimentally show that mutant Shank2 is also dominant over WT Shank2. However, we find this type of triple transfection (shRNA + two expression vectors) of neurons difficult to perform in a controlled manner, as we cannot determine whether equal amounts of both proteins are expressed. Due to the low percentage of transfected cells, our cultured neurons are not susceptible to Western Blot analysis, which would be the proper way to do this.
In summary, our data for the first time show that PDZ- and SAM-domain mediated interactions of Shank proteins are required for shaping and compaction of postsynaptic nanoclusters, and that this is relevant for the healthy development of the human nervous system.
Sheng M, Kim E. The Shank family of scaffold proteins. J Cell Sci. 2000;113:1851.
Guilmatre A, Huguet G, Delorme R, Bourgeron T. The emerging role of SHANK genes in neuropsychiatric disorders. Dev Neurobiol. 2014;74:113–22.
Naisbitt S, Kim E, Tu JC, Xiao B, Sala C, Valtschanoff J, et al. Shank, a Novel Family of Postsynaptic Density Proteins that Binds to the NMDA Receptor/PSD-95/GKAP Complex and Cortactin. Neuron. 1999;23:569–82.
Boeckers TM, Winter C, Smalla K-H, Kreutz MR, Bockmann J, Seidenbecher C, et al. Proline-Rich Synapse-Associated Proteins ProSAP1 and ProSAP2 Interact with Synaptic Proteins of the SAPAP/GKAP Family. Biochem Biophys Res Commun. 1999;264:247–52.
Du Y, Weed SA, Xiong W-C, Marshall TD, Parsons JT. Identification of a Novel Cortactin SH3 Domain-Binding Protein and Its Localization to Growth Cones of Cultured Neurons. Mol Cell Biol. 1998;18:5838.
Wu H, Parsons JT. Cortactin, an 80/85-kilodalton pp60src substrate, is a filamentous actin-binding protein enriched in the cell cortex. J Cell Biol. 1993;120:1417.
Bockmann J, Kreutz MR, Gundelfinger ED, Böckers TM. ProSAP/Shank postsynaptic density proteins interact with insulin receptor tyrosine kinase substrate IRSp53. J Neurochemistry. 2002;83:1013–7.
Proepper C, Johannsen S, Liebau S, Dahl J, Vaida B, Bockmann J, et al. Abelson interacting protein 1 (Abi-1) is essential for dendrite morphogenesis and synapse formation. EMBO J. 2007;26:1397–409.
Boeckers TM, Kreutz MR, Winter C, Zuschratter W, Smalla K-H, Sanmarti-Vila L, et al. Proline-rich synapse-associated protein-1/cortactin binding protein 1 (ProSAP1/CortBP1) is a PDZ-domain protein highly enriched in the postsynaptic density. J Neurosci 1999;19:6506–18
Soltau M, Richter D, Kreienkamp H-J. The Insulin Receptor Substrate IRSp53 Links Postsynaptic shank1 to the Small G-Protein cdc42. Mol Cell Neurosci. 2002;21:575–83.
Tu JC, Xiao B, Naisbitt S, Yuan JP, Petralia RS, Brakeman P, et al. Coupling of mGluR/Homer and PSD-95 Complexes by the Shank Family of Postsynaptic Density Proteins. Neuron. 1999;23:583–92.
Xiao B, Tu JC, Petralia RS, Yuan JP, Doan A, Breder CD, et al. Homer Regulates the Association of Group 1 Metabotropic Glutamate Receptors with Multivalent Complexes of Homer-Related, Synaptic Proteins. Neuron. 1998;21:707–16.
Baron MK, Boeckers TM, Vaida B, Faham S, Gingery M, Sawaya MR, et al. An Architectural Framework That May Lie at the Core of the Postsynaptic Density. Science. 2006;311:531.
MacGillavry HD, Song Y, Raghavachari S, Blanpied TA. Nanoscale scaffolding domains within the postsynaptic density concentrate synaptic AMPA receptors. Neuron. 2013;78:615–22.
Hruska M, Henderson N, Le Marchand SJ, Jafri H, Dalva MB. Synaptic nanomodules underlie the organization and plasticity of spine synapses. Nat Neurosci. 2018;21:671–82.
Leblond CS, Nava C, Polge A, Gauthier J, Huguet G, Lumbroso S, et al. Meta-analysis of SHANK Mutations in Autism Spectrum Disorders: a gradient of severity in cognitive impairments. PLoS Genet. 2014;10:e1004580.
Berkel S, Marshall CR, Weiss B, Howe J, Roeth R, Moog U, et al. Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation. Nat Genet. 2010;42:489–91.
Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R, et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature. 2010;466:368–72.
Wischmeijer A, Magini P, Giorda R, Gnoli M, Ciccone R, Cecconi L, et al. Olfactory Receptor-Related Duplicons Mediate a Microdeletion at 11q13.2q13.4 Associated with a Syndromic Phenotype. Mol Syndromol. 2011;1:176–84.
Leblond CS, Heinrich J, Delorme R, Proepper C, Betancur C, Huguet G, et al. Genetic and functional analyses of SHANK2 mutations suggest a multiple hit model of autism spectrum disorders. PLoS Genet. 2012;8:e1002521.
Chilian B, Abdollahpour H, Bierhals T, Haltrich I, Fekete G, Nagel I, et al. Dysfunction of SHANK2 and CHRNA7 in a patient with intellectual disability and language impairment supports genetic epistasis of the two loci. Clin Genet. 2013;84:560–5.
Schluth-Bolard C, Labalme A, Cordier MP, Till M, Nadeau G, Tevissen H, et al. Breakpoint mapping by next generation sequencing reveals causative gene disruption in patients carrying apparently balanced chromosome rearrangements with intellectual deficiency and/or congenital malformations. J Med Genet. 2013;50:144–50.
Peykov S, Berkel S, Schoen M, Weiss K, Degenhardt F, Strohmaier J, et al. Identification and functional characterization of rare SHANK2 variants in schizophrenia. Mol Psychiatry. 2015;20:1489–98.
Homann OR, Misura K, Lamas E, Sandrock RW, Nelson P, McDonough SI, et al. Whole-genome sequencing in multiplex families with psychoses reveals mutations in the SHANK2 and SMARCA1 genes segregating with illness. Mol Psychiatry. 2016;21:1690–5.
Hassani Nia F, Kreienkamp HJ. Functional Relevance of Missense Mutations Affecting the N-Terminal Part of Shank3 Found in Autistic Patients. Front Mol Neurosci. 2018;11:268.
Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F, et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet. 2007;39:25–7.
Gauthier J, Spiegelman D, Piton A, Lafreniere RG, Laurent S, St-Onge J, et al. Novel de novo SHANK3 mutation in autistic patients. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:421–4.
Woike D, Wang E, Tibbe D, Hassani Nia F, Failla AV, Kibaek M, et al. Mutations affecting the N-terminal domains of SHANK3 point to different pathomechanisms in neurodevelopmental disorders. Sci Rep. 2022;12:902.
Berkel S, Tang W, Trevino M, Vogt M, Obenhaus HA, Gass P, et al. Inherited and de novo SHANK2 variants associated with autism spectrum disorder impair neuronal morphogenesis and physiology. Hum Mol Genet. 2012;21:344–57.
Bucher M, Niebling S, Han Y, Molodenskiy D, Hassani Nia F, Kreienkamp HJ, et al. Autism-associated SHANK3 missense point mutations impact conformational fluctuations and protein turnover at synapses. Elife. 2021;10:e66165.
Keller S, Vargas C, Zhao H, Piszczek G, Brautigam CA, Schuck P. High-precision isothermal titration calorimetry with automated peak-shape analysis. Anal Chem. 2012;84:5066–73.
Zhao H, Piszczek G, Schuck P. SEDPHAT-a platform for global ITC analysis and global multi-method analysis of molecular interactions. Methods. 2015;76:137–48.
Brautigam CA, Zhao H, Vargas C, Keller S, Schuck P. Integration and global analysis of isothermal titration calorimetry data for studying macromolecular interactions. Nat Protoc. 2016;11:882–94.
Knight MJ, Joubert MK, Plotkowski ML, Kropat J, Gingery M, Sakane F, et al. Zinc binding drives sheet formation by the SAM domain of diacylglycerol kinase δ. Biochemistry 2010;49:9667–76.
Kabsch W. Xds. Acta Crystallogr D Biol Crystallogr. 2010;66:125–32.
Evans PR. An introduction to data reduction: space-group determination, scaling and intensity statistics. Acta Crystallogr D Biol Crystallogr. 2011;67:282–92.
Vagin A, Teplyakov A. Molecular replacement with MOLREP. Acta Crystallogr D Biol Crystallogr. 2010;66:22–5.
Murshudov GN, Skubak P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr. 2011;67:355–67.
Afonine PV, Grosse-Kunstleve RW, Echols N, Headd JJ, Moriarty NW, Mustyakimov M, et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr D Biol Crystallogr. 2012;68:352–67.
Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60:2126–32.
Potterton L, Agirre J, Ballard C, Cowtan K, Dodson E, Evans PR, et al. CCP4i2: the new graphical user interface to the CCP4 program suite. Acta Crystallogr D Struct Biol. 2018;74:68–84.
Joosten RP, Salzemann J, Bloch V, Stockinger H, Berglund AC, Blanchet C, et al. PDB_REDO: automated re-refinement of X-ray structure models in the PDB. J Appl Crystallogr. 2009;42:376–84.
Williams CJ, Headd JJ, Moriarty NW, Prisant MG, Videau LL, Deis LN, et al. MolProbity: More and better reference data for improved all-atom structure validation. Protein Sci. 2018;27:293–315.
Hassani Nia F, Woike D, Kloth K, Kortum F, Kreienkamp HJ Truncating mutations in SHANK3 associated with global developmental delay interfere with nuclear beta-catenin signaling. J Neurochem. 2020;155:250–63.
Hassani Nia F, Woike D, Martens V, Klussendorf M, Honck HH, Harder S, et al. Targeting of delta-catenin to postsynaptic sites through interaction with the Shank3 N-terminus. Mol Autism. 2020;11:85.
Lilja J, Zacharchenko T, Georgiadou M, Jacquemet G, De Franceschi N, Peuhu E, et al. SHANK proteins limit integrin activation by directly interacting with Rap1 and R-Ras. Nat Cell Biol. 2017;19:292–305.
Salomaa SI, Miihkinen M, Kremneva E, Paatero I, Lilja J, Jacquemet G, et al. SHANK3 conformation regulates direct actin binding and crosstalk with Rap1 signaling. Curr Biol. 2021;31:4956–70.
Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46:310–5.
Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum Mutat. 2015;36:928–30.
Zeng M, Shang Y, Guo T, He Q, Yung WH, Liu K, et al. A binding site outside the canonical PDZ domain determines the specific interaction between Shank and SAPAP and their function. Proc Natl Acad Sci USA. 2016;113:E3081–90.
Doyle DA, Lee A, Lewis J, Kim E, Sheng M, MacKinnon R. Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ. Cell. 1996;85:1067–76.
Im YJ, Lee JH, Park SH, Park SJ, Rho SH, Kang GB, et al. Crystal structure of the Shank PDZ-ligand complex reveals a class I PDZ interaction and a novel PDZ-PDZ dimerization. J Biol Chem. 2003;278:48099–104.
Kreienkamp HJ, Zitzer H, Gundelfinger ED, Richter D, Bockers TM. The calcium-independent receptor for alpha-latrotoxin from human and rodent brains interacts with members of the ProSAP/SSTRIP/Shank family of multidomain proteins. J Biol Chem. 2000;275:32387–90.
Benson DL, Watkins FH, Steward O, Banker G. Characterization of GABAergic neurons in hippocampal cell cultures. J Neurocytol. 1994;23:279–95.
Doddato G, Fabbiani A, Scandurra V, Canitano R, Mencarelli MA, Renieri A, et al. Identification of a Novel SHANK2 Pathogenic Variant in a Patient with a Neurodevelopmental Disorder. Genes. 2022;13:688.
Vyas Y, Jung Y, Lee K, Garner CC, Montgomery JM. In vitro zinc supplementation alters synaptic deficits caused by autism spectrum disorder-associated Shank2 point mutations in hippocampal neurons. Mol Brain. 2021;14:95.
Won H, Lee HR, Gee HY, Mah W, Kim JI, Lee J, et al. Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature. 2012;486:261–5.
Schmeisser MJ, Ey E, Wegener S, Bockmann J, Stempel AV, Kuebler A, et al. Autistic-like behaviours and hyperactivity in mice lacking ProSAP1/Shank2. Nature. 2012;486:256–60.
Peca J, Feliciano C, Ting JT, Wang W, Wells MF, Venkatraman TN, et al. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature. 2011;472:437–42.
Mossa A, Pagano J, Ponzoni L, Tozzi A, Vezzoli E, Sciaccaluga M, et al. Developmental impaired Akt signaling in the Shank1 and Shank3 double knock-out mice. Mol Psychiatry. 2021;26:1928–44.
Garrido D, Beretta S, Grabrucker S, Bauer HF, Bayer D, Sala C, et al. Shank2/3 double knockout-based screening of cortical subregions links the retrosplenial area to the loss of social memory in autism spectrum disorders. Mol Psychiatry. 2022 https://doi.org/10.1038/s41380-022-01756-8.
Sala C, Piëch V, Wilson NR, Passafaro M, Liu G, Sheng M. Regulation of Dendritic Spine Morphology and Synaptic Function by Shank and Homer. Neuron. 2001;31:115–30.
Boeckers TM, Liedtke T, Spilker C, Dresbach T, Bockmann J, Kreutz MR, et al. C-terminal synaptic targeting elements for postsynaptic density proteins ProSAP1/Shank2 and ProSAP2/Shank3. J Neurochem. 2005;92:519–24.
Grabrucker AM, Knight MJ, Proepper C, Bockmann J, Joubert M, Rowan M, et al. Concerted action of zinc and ProSAP/Shank in synaptogenesis and synapse maturation. EMBO J. 2011;30:569–81.
Grabrucker S, Boeckers TM, Grabrucker AM. Gender Dependent Evaluation of Autism like Behavior in Mice Exposed to Prenatal Zinc Deficiency. Front Behav Neurosci. 2016;10:37.
Grabrucker S, Jannetti L, Eckert M, Gaub S, Chhabra R, Pfaender S, et al. Zinc deficiency dysregulates the synaptic ProSAP/Shank scaffold and might contribute to autism spectrum disorders. Brain. 2014;137:137–52.
Zeng M, Chen X, Guan D, Xu J, Wu H, Tong P, et al. Reconstituted Postsynaptic Density as a Molecular Platform for Understanding Synapse Formation and Plasticity. Cell. 2018;174:1172–87.e16.
Lessel D, Schob C, Kury S, Reijnders MRF, Harel T, Eldomery MK, et al. De Novo Missense Mutations in DHX30 Impair Global Translation and Cause a Neurodevelopmental Disorder. Am J Hum Genet. 2017;101:716–24.
Lessel D, Zeitler DM, Reijnders MRF, Kazantsev A, Hassani Nia F, Bartholomaus A, et al. Germline AGO2 mutations impair RNA interference and human neurological development. Nat Commun. 2020;11:5797.
Mannucci I, Dang NDP, Huber H, Murry JB, Abramson J, Althoff T, et al. Genotype-phenotype correlations and novel molecular insights into the DHX30-associated neurodevelopmental disorders. Genome Med. 2021;13:90.
We thank S. Berkel (Heidelberg) and S. Kindler (Hamburg) for expression plasmids. We acknowledge technical support by the SPC facility at EMBL Hamburg and would like to thank for the support received at P14 beamline operated by EMBL at the PETRA III storage ring (DESY, Hamburg).
Open Access funding enabled and organized by Projekt DEAL. Financial support by Deutsche Forschungsgemeinschaft (grants Kr1321/9-1, to HJK; SFB 1328, project number 335447717, to DH and CL) isacknowledged. This work benefited from access to EMBL HH and has been supported by iNEXT-Discovery, project number 871037, funded by the Horizon 2020 program of the European Commission.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Hassani Nia, F., Woike, D., Bento, I. et al. Structural deficits in key domains of Shank2 lead to alterations in postsynaptic nanoclusters and to a neurodevelopmental disorder in humans. Mol Psychiatry (2022). https://doi.org/10.1038/s41380-022-01882-3